Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Zai Lab Ltd ( (HK:9688) ) is now available.
Zai Lab Ltd has announced the grant of share options, restricted share units, and performance share units under its 2024 Equity Incentive Plan. This move, which includes significant allocations to key personnel such as Dr. Samantha Du, aims to align the interests of employees with the company’s growth objectives and maintain competitive compensation practices. The grants are structured without performance targets or clawback mechanisms, reflecting the company’s customary practices and market competitiveness.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Ltd is a biopharmaceutical company focused on developing and commercializing innovative medicines, primarily in the fields of oncology, autoimmune disorders, and infectious diseases. The company operates with a market focus on bringing transformative therapies to patients in China and globally.
Average Trading Volume: 12,847,838
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.87B
Find detailed analytics on 9688 stock on TipRanks’ Stock Analysis page.